Embolic protection device enters US trial:
This article was originally published in Clinica
Executive Summary
A multicentre clinical trial of Embolic Protection's filter for removing particles and blood clots during angioplasty and vascular interventions is underway in the US. The FilterWire EX is initially being assessed in 30 saphenous vein graft interventions, but a larger safety and efficacy trial is planned for early next year, says the Campbell, California company. The filter is attached to a 0.014 inch guidewire and can be inserted into a vessel through a 3F catheter. It allows blood to flow continuously through a vessel and can pass through much smaller arteries compared with other embolic protection devices, Milt McColl, Embolic's chief medical officer told Clinica.
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.